Although the cancer progression phenotypes induced by ALK4 loss were consistent across breast and pancreatic cancer models, the in vivo and mechanistic validation is more extensive in pancreatic cancer models. This evidence concerns the gene ACVR1B and familial pancreatic carcinoma.